Wei Chang Zhou
Director/Board Member at WUXI BIOLOGICS (CAYMAN) INC.
Net worth: 613 268 $ as of 30/05/2024
Profile
Currently, Weichang Zhou occupies the position of Executive Director, Chief Technology Officer & EVP at Wuxi Biologics (Cayman), Inc. He previously occupied the position of Associate Director at Merck & Co., Inc. Dr. Zhou received an undergraduate degree from Jiangxi University of Science & Technology and a doctorate from the University of Hannover.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 11/06/2024 | 430,684 ( 0.01% ) | 613 268 $ | 30/05/2024 |
Wei Chang Zhou active positions
| Companies | Position | Start |
|---|---|---|
| WUXI BIOLOGICS (CAYMAN) INC. | Director/Board Member | 30/04/2016 |
| WUXI XDC CAYMAN INC. | Director/Board Member | 30/11/2020 |
Former positions of Wei Chang Zhou
| Companies | Position | End |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Director/Board Member | 30/11/2012 |
| PDL BIOPHARMA, INC. | Director/Board Member | 31/01/2008 |
| MERCK & CO., INC. | Corporate Officer/Principal | 30/09/2002 |
Training of Wei Chang Zhou
| Jiangxi University of Science & Technology | Undergraduate Degree |
| University of Hannover | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| WUXI BIOLOGICS (CAYMAN) INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| WUXI XDC CAYMAN INC. | Commercial Services |
| Private companies | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Stock Market
- Insiders
- Wei Chang Zhou
